Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine

Representing an enormous health care and socioeconomic challenge, breast cancer is the second most common cancer in the world and the second most common cause of cancer-related death. Although many of the challenges associated with preventing, treating, and ultimately curing breast cancer are addressable in the laboratory, successful translation of groundbreaking research to clinical populations remains an important barrier. Particularly when compared with research on other types of solid tumors, breast cancer research is hampered by a lack of tractable in vivo model systems that accurately recapitulate the relevant clinical features of the disease. A primary objective of this article was to provide a generalizable overview of the types of in vivo model systems, with an emphasis primarily on murine models, that are widely deployed in preclinical breast cancer research. Major opportunities to advance precision cancer medicine facilitated by molecular imaging of preclinical breast cancer models are discussed.

[1]  D. Kiesewetter,et al.  Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model , 2012, The Journal of Nuclear Medicine.

[2]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[3]  S. Lyons,et al.  Imaging Mouse Models of Cancer. , 2015, Cancer journal.

[4]  S. Orsulic,et al.  Mouse models of cancer. , 2011, Annual review of pathology.

[5]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[6]  Giovanni Parmigiani,et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.

[7]  S. Modi,et al.  HER2 breast cancer therapies: a review , 2009, Biologics : targets & therapy.

[8]  Robert A. Weinberg,et al.  Comparative Biology of Mouse versus Human Cells: Modelling Human Cancer in Mice O P I N I O N , 2022 .

[9]  Todd E Peterson,et al.  Molecular Imaging: 18F-FDG PET and a Whole Lot More* , 2009, Journal of Nuclear Medicine Technology.

[10]  Andrew L. Kung,et al.  Examining the utility of patient-derived xenograft mouse models , 2015, Nature Reviews Cancer.

[11]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[12]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[13]  G. Hospers,et al.  PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma , 2012, The Journal of Nuclear Medicine.

[14]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[15]  Christof Fellmann,et al.  Stable RNA interference rules for silencing , 2013, Nature Cell Biology.

[16]  M. Washington,et al.  A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells , 2014, Clinical Cancer Research.

[17]  Eliot T. McKinley,et al.  [18F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study , 2015, Annals of Nuclear Medicine.

[18]  Karlyne M. Reilly,et al.  Genetically engineered mouse models in cancer research. , 2010, Advances in cancer research.

[19]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[20]  P. Pandolfi,et al.  A co-clinical platform to accelerate cancer treatment optimization. , 2015, Trends in molecular medicine.

[21]  V. Cryns,et al.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.

[22]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[23]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[24]  C. Dence,et al.  Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer , 2012, The Journal of Nuclear Medicine.

[25]  Jason I. Herschkowitz,et al.  Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.

[26]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[27]  Ping Zhao,et al.  Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer , 2009, Clinical Cancer Research.

[28]  Hakmook Kang,et al.  Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts , 2015, Molecular Imaging and Biology.

[29]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[30]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[31]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients , 2015, EJNMMI Research.

[32]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[33]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[34]  Samir J. Courdy,et al.  Patient‐Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine , 2013, Current protocols in pharmacology.

[35]  Peter J Houghton,et al.  Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.

[36]  Gerhard Christofori,et al.  Mouse models of breast cancer metastasis , 2006, Breast Cancer Research.

[37]  Eliot T. McKinley,et al.  3′-Deoxy-3′-[18F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer , 2014, PloS one.

[38]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[39]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[40]  A. Nunn,et al.  (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. , 2015, Nuclear medicine and biology.

[41]  J. P. Kennedy,et al.  Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells , 2009, Clinical Cancer Research.

[42]  John N. Hutchinson,et al.  Transgenic mouse models of human breast cancer , 2000, Oncogene.

[43]  S. Schnitt,et al.  Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.